哌拉西林钠他唑巴坦钠联合莫西沙星治疗 慢性阻塞性肺疾病合并急性下呼吸道感染的 效果

打开文本图片集

[Abstract] Objective：To study the efficacy of Piperacillin Sodium Tazobactam Sodium in combination with Moxifloxacin in the treatment of chronic obstructive pulmonary disease （COPD） complicated with acute lower respiratory infection （ALRI）.Method： A total of 12O patients with COPD complicated with ALRI admitted toShijingshan Teaching Hospital of CapitalMedical Universitywere selected retrospectively，admision period was from January 2O21 to December 2O23，they were divided into a single group （Moxifloxacin，60 cases）and a combination group （Piperacillin Sodium Tazobactam Sodium + Moxifloxacin，6O cases）with reference to the dierent treatments.Both groups were treated for1O days.The inflammatory factors[IL-6，IL-8，TNF- α ，CRP， and procalcitonin （PCT）]levels，acute physiologyand chronic health evaluation II （APACHEII）scores before and after treatment，andthe total effectiverate aftertreatment，and theadverse reactions （headache，diarrhea，nausea and vomiting） incidence in the two groups were compared.Result： Compared with pre-treatment，post-treatment levels of IL-6， IL-8， TNF- ∝ ，CRP，and PCT were lower in the single group and the combination group （ P <0.05）.

Compared with the single group，post-treatment levels of IL-6， IL-8， TNF- ∝ ，CRP，and PCT were lower in the combination group （P<0.05 ）.Compared with pre-treatment， APACHEI scores were lower in the single group and the combination group after treatment （ P<0.05 ；compared with the single group，APACHEII score was lower in the combination group after treatment （ P <0.05）.The total effective rate in the combination group （96.67% ）washigher than that in the single group （85.00% 0 P <0.05）.There was no statistically significant difference in the incidence of headache，diarrea，or nausea and vomiting between the single group and the combination group （P>0.05）. Conclusion：Piperacillin Sodium Tazobactam Sodium combined with Moxifloxacin is highly efficacious in the treatment of COPD complicated with ALRI，significantly reducing the levels of inflammatory factors.

[KeyWords] Piperacillin Sodium Tazobactam Sodium Moxifloxacin Chronic obstructive pulmonary diseaseAcute lower respiratory infection Inflammatory factors

First-author's address： The Emergency Department of Shijingshan Teaching Hospital of Capital Medical University，Beijing 10oo41， China

doi：10.3969/j.issn.1674-4985.2026.08.022

慢性阻塞性肺疾病（chronic obstructive pulmonarydisease，COPD）是肺部病症，患病人数逐年增多，致病因素以空气污染、长期吸烟等为主，表现以呼吸困难、肺功能减弱、咳痰及咳嗽为主，受长期用药、免疫力下降、呼吸道结构变化等因素影响，易伴发急性下呼吸道感染（acute lower respiratoryinfection，ALRI），不仅会加重心脏负担、呼吸困难症状，还可能诱发呼吸衰竭，危及生命[1-3]。（剩余4960字）